{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:39:56Z","timestamp":1788910796552,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>STAT3 and p-STAT3 are often overexpressed in various human tumours and participate in cancer development and progression. However, whether STAT3\/p-STAT3 expression is associated with clinicopathologic characteristics and has prognostic significance for people suffering from ovarian cancer remains controversial. We conducted a systematic review and meta-analyses to clarify the associations between STAT3\/p-STAT3 expression and clinicopathologic characteristics and prognostic factors of ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic electronic search in the PubMed, Embase, CNKI, and Wanfang databases was conducted to identify relevant articles published before 3 April 2021. All statistical analyses were performed using Stata 15.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 16 eligible studies incorporating 1747 ovarian cancer patients. The expression of STAT3\/p-STAT3 was upregulated in ovarian cancer samples versus normal ovarian tissue, benign tumours and borderline tumours (OR\u2009=\u200910.14,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001; OR\u2009=\u20099.08,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001; OR\u2009=\u20094.01,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001, respectively). STAT3\/p-STAT3 overexpression was significantly correlated with FIGO stage (I-II vs. III-IV) (OR\u2009=\u20090.36,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001), tumour grade (G1\u2009+\u2009G2 vs. G3) (OR\u2009=\u20090.55;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and lymph node metastasis (yes vs. no) (OR\u2009=\u20093.39;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001). High STAT3\/p-STAT3 expression was correlated with poorer prognosis of ovarian cancer patients for both overall survival (OS) (HR\u2009=\u20091.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001) and progression-free survival (PFS) (HR\u2009=\u20091.40,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present meta-analysis indicated that high STAT3\/p-STAT3 expression is likely predictive of an unfavourable prognosis in ovarian cancer patients. Nonetheless, prospective trials are required to confirm these associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-021-00918-6","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T22:03:07Z","timestamp":1637186587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The impact of STAT3 and phospho-STAT3 expression on the prognosis and clinicopathology of ovarian cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0068-5287","authenticated-orcid":false,"given":"Shuo","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-4759","authenticated-orcid":false,"given":"Jinhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"issue":"3 Pt 1","key":"918_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.AOG.0000231680.58221.a7","volume":"108","author":"JK Chan","year":"2006","unstructured":"Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years[J]. Obstet Gynecol. 2006;108(3 Pt 1):521\u20138.","journal-title":"Obstet Gynecol"},{"key":"918_CR2","volume-title":"International agency for research on cancer","author":"World Cancer Report","year":"2008","unstructured":"World Cancer Report. International agency for research on cancer. Lyon: World Cancer Report; 2008."},{"issue":"12","key":"918_CR3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1080\/00016340802495491","volume":"87","author":"M Akeson","year":"2008","unstructured":"Akeson M, Zetterqvist BM, Dahll\u00f6f K, et al. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up[J]. Acta Obstet Gynecol Scand. 2008;87(12):1343\u201352.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"5332","key":"918_CR4","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","volume":"277","author":"JE Darnell Jr","year":"1997","unstructured":"Darnell JE Jr. STATs and gene regulation[J]. Science. 1997;277(5332):1630\u20135.","journal-title":"Science"},{"issue":"21","key":"918_CR5","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis[J]. Oncogene. 2000;19(21):2474\u201388.","journal-title":"Oncogene"},{"issue":"4","key":"918_CR6","first-page":"e24935","volume":"2","author":"Y Tang","year":"2013","unstructured":"Tang Y, Tian XC. JAK-STAT3 and somatic cell reprogramming[J]. Jakstat. 2013;2(4):e24935.","journal-title":"Jakstat"},{"issue":"12","key":"918_CR7","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.3168\/jds.2009-2439","volume":"92","author":"H Khatib","year":"2009","unstructured":"Khatib H, Huang W, Mikheil D, et al. Effects of signal transducer and activator of transcription (STAT) genes STAT1 and STAT3 genotypic combinations on fertilization and embryonic survival rates in Holstein cattle[J]. J Dairy Sci. 2009;92(12):6186\u201391.","journal-title":"J Dairy Sci"},{"issue":"8","key":"918_CR8","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/ph6080960","volume":"6","author":"A Weber","year":"2013","unstructured":"Weber A, Borghouts C, Brendel C, et al. The inhibition of stat5 by a peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells[J]. Pharmaceuticals (Basel). 2013;6(8):960\u201387.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"918_CR9","first-page":"e27363","volume":"2","author":"M Geletu","year":"2013","unstructured":"Geletu M, Guy S, Arulanandam R, et al. Engaged for survival: from cadherin ligation to STAT3 activation[J]. Jakstat. 2013;2(4):e27363.","journal-title":"Jakstat"},{"key":"918_CR10","doi-asserted-by":"publisher","first-page":"8833885","DOI":"10.1155\/2020\/8833885","volume":"2020","author":"B Liang","year":"2020","unstructured":"Liang B, Li SY, Gong HZ, et al. Clinicopathological and prognostic roles of STAT3 and its phosphorylation in glioma[J]. Dis Markers. 2020;2020:8833885.","journal-title":"Dis Markers"},{"issue":"1","key":"918_CR11","doi-asserted-by":"publisher","first-page":"11243","DOI":"10.1038\/s41598-019-47556-z","volume":"9","author":"Y Li","year":"2019","unstructured":"Li Y, Wang Y, Shi Z, et al. Clinicopathological and prognostic role of STAT3\/p-STAT3 in breast cancer patients in China: a meta-analysis[J]. Sci Rep. 2019;9(1):11243.","journal-title":"Sci Rep"},{"issue":"16","key":"918_CR12","doi-asserted-by":"publisher","first-page":"13060","DOI":"10.18632\/oncotarget.23962","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Huang J, Li W, et al. Meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with breast cancer[J]. Oncotarget. 2018;9(16):13060\u20137.","journal-title":"Oncotarget"},{"issue":"8","key":"918_CR13","doi-asserted-by":"publisher","first-page":"e0182282","DOI":"10.1371\/journal.pone.0182282","volume":"12","author":"M Tong","year":"2017","unstructured":"Tong M, Wang J, Jiang N, et al. Correlation between p-STAT3 overexpression and prognosis in lung cancer: a systematic review and meta-analysis[J]. PLoS One. 2017;12(8):e0182282.","journal-title":"PLoS One"},{"issue":"3","key":"918_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ejso.2013.11.012","volume":"40","author":"YH Xu","year":"2014","unstructured":"Xu YH, Lu S. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer[J]. Eur J Surg Oncol. 2014;40(3):311\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"918_CR15","doi-asserted-by":"publisher","first-page":"e0160125","DOI":"10.1371\/journal.pone.0160125","volume":"11","author":"K Ji","year":"2016","unstructured":"Ji K, Zhang M, Chu Q, et al. The role of p-STAT3 as a prognostic and clinicopathological marker in colorectal cancer: a systematic review and meta-analysis[J]. PLoS One. 2016;11(8):e0160125.","journal-title":"PLoS One"},{"issue":"9","key":"918_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"918_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials. 2007;8:16.","journal-title":"Trials"},{"issue":"11","key":"918_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis[J]. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7109","key":"918_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"4","key":"918_CR20","first-page":"5772","volume":"15","author":"T Yoshikawa","year":"2018","unstructured":"Yoshikawa T, Miyamoto M, Aoyama T, et al. JAK2\/STAT3 pathway as a therapeutic target in ovarian cancers[J]. Oncol Lett. 2018;15(4):5772\u201380.","journal-title":"Oncol Lett"},{"issue":"1","key":"918_CR21","doi-asserted-by":"publisher","first-page":"e54029","DOI":"10.1371\/journal.pone.0054029","volume":"8","author":"C Yang","year":"2013","unstructured":"Yang C, Lee H, Jove V, et al. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer[J]. PLoS One. 2013;8(1):e54029.","journal-title":"PLoS One"},{"issue":"5","key":"918_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/j.1447-0756.2009.01045.x","volume":"35","author":"H Min","year":"2009","unstructured":"Min H, Wei-Hong Z. Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma[J]. J Obstet Gynaecol Res. 2009;35(5):918\u201325.","journal-title":"J Obstet Gynaecol Res"},{"issue":"5","key":"918_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/15384047.2017.1310343","volume":"18","author":"AQ Shang","year":"2017","unstructured":"Shang AQ, Wu J, Bi F, et al. Relationship between HER2 and JAK\/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer[J]. Cancer Biol Ther. 2017;18(5):314\u201322.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"918_CR24","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1002\/cncr.22293","volume":"107","author":"DG Rosen","year":"2006","unstructured":"Rosen DG, Mercado-Uribe I, Yang G, et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis[J]. Cancer. 2006;107(11):2730\u201340.","journal-title":"Cancer"},{"issue":"08","key":"918_CR25","first-page":"742","volume":"25","author":"FC Xiao","year":"2015","unstructured":"Xiao FC, Zhang CL, Fang R, et al. Expression and correlation of p-STAT3 and FHIT in epithelial ovarian tumors[J]. Zhejiang JITCWM. 2015;25(08):742\u20134 Chinese.","journal-title":"Zhejiang JITCWM"},{"issue":"03","key":"918_CR26","first-page":"336","volume":"25","author":"ZP Gao","year":"2013","unstructured":"Gao ZP, Wang ZP, Xu Y, et al. Expression and significance of STAT3 and phosphatase gene proteins in epithelial ovarian neoplasms[J]. Mod Pract Med. 2013;25(03):336\u20138 chinese.","journal-title":"Mod Pract Med"},{"issue":"8","key":"918_CR27","doi-asserted-by":"publisher","first-page":"e23777","DOI":"10.1097\/MD.0000000000023777","volume":"100","author":"D Wu","year":"2021","unstructured":"Wu D, Lei Y, Liu Q, et al. Characterization and clinical significance of the CADM1\/HER2\/STAT3 axis in serous ovarian tumors[J]. Medicine (Baltimore). 2021;100(8):e23777.","journal-title":"Medicine (Baltimore)"},{"key":"918_CR28","unstructured":"Zhang J, Li YH, Cui AR, et al. Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma. [J]. Chin J Oncol. 2008;(12):905\u20139 chinese."},{"issue":"8","key":"918_CR29","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1158\/0008-5472.CAN-16-1115","volume":"77","author":"MW Chen","year":"2017","unstructured":"Chen MW, Yang ST, Chien MH, et al. The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer[J]. Cancer Res. 2017;77(8):1955\u201367.","journal-title":"Cancer Res"},{"issue":"1","key":"918_CR30","doi-asserted-by":"publisher","first-page":"e12719","DOI":"10.1111\/cpr.12719","volume":"53","author":"H Li","year":"2020","unstructured":"Li H, Qian Y, Wang X, et al. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden[J]. Cell Prolif. 2020;53(1):e12719.","journal-title":"Cell Prolif"},{"issue":"5","key":"918_CR31","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/mc.22325","volume":"55","author":"N Yanaihara","year":"2016","unstructured":"Yanaihara N, Hirata Y, Yamaguchi N, et al. Antitumor effects of interleukin-6 (IL-6)\/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary[J]. Mol Carcinog. 2016;55(5):832\u201341.","journal-title":"Mol Carcinog"},{"issue":"12","key":"918_CR32","doi-asserted-by":"publisher","first-page":"e962397","DOI":"10.4161\/21624011.2014.962397","volume":"3","author":"M Wouters","year":"2014","unstructured":"Wouters M, Dijkgraaf EM, Kuijjer ML, et al. Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer[J]. Oncoimmunology. 2014;3(12):e962397.","journal-title":"Oncoimmunology"},{"issue":"7","key":"918_CR33","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.celrep.2016.04.034","volume":"15","author":"P Chaluvally-Raghavan","year":"2016","unstructured":"Chaluvally-Raghavan P, Jeong KJ, Pradeep S, et al. Direct upregulation of STAT3 by MicroRNA-551b-3p deregulates growth and metastasis of ovarian cancer[J]. Cell Rep. 2016;15(7):1493\u2013504.","journal-title":"Cell Rep"},{"issue":"06","key":"918_CR34","first-page":"427","volume":"33","author":"DD Guan","year":"2010","unstructured":"Guan DD, Cao SY, Huang JZ, et al. The effect of STAT3 expression on dendritlc cell in ovarian epithelial carcinoma[J]. BMU J. 2010;33(06):427\u2013429+432 chinese.","journal-title":"BMU J"},{"issue":"24","key":"918_CR35","first-page":"118","volume":"14","author":"L Hong","year":"2017","unstructured":"Hong L, Yang J, Xing H, et al. Expression of signal transducer and activators of transcription 3 and Twist basic helix-loop-helix transcription factor 1 in epithelial ovarian cancer [J]. China Med Herald. 2017;14(24):118\u2013121+195 chinese.","journal-title":"China Med Herald"},{"issue":"1","key":"918_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","volume":"12","author":"T Gritsko","year":"2006","unstructured":"Gritsko T, Williams A, Turkson J, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells[J]. Clin Cancer Res. 2006;12(1):11\u20139.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"918_CR37","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-05-2674","volume":"66","author":"TX Xie","year":"2006","unstructured":"Xie TX, Huang FJ, Aldape KD, et al. Activation of stat3 in human melanoma promotes brain metastasis[J]. Cancer Res. 2006;66(6):3188\u201396.","journal-title":"Cancer Res"},{"issue":"11","key":"918_CR38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3[J]. Nat Rev Cancer. 2009;9(11):798\u2013809.","journal-title":"Nat Rev Cancer"},{"issue":"7279","key":"918_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature08712","volume":"463","author":"MS Carro","year":"2010","unstructured":"Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours[J]. Nature. 2010;463(7279):318\u201325.","journal-title":"Nature"},{"issue":"4","key":"918_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccr.2011.03.004","volume":"19","author":"OA Guryanova","year":"2011","unstructured":"Guryanova OA, Wu Q, Cheng L, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3[J]. Cancer Cell. 2011;19(4):498\u2013511.","journal-title":"Cancer Cell"},{"issue":"3","key":"918_CR41","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.18632\/oncotarget.23226","volume":"9","author":"X Cui","year":"2018","unstructured":"Cui X, Jing X, Yi Q, et al. Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer[J]. Oncotarget. 2018;9(3):3198\u2013213.","journal-title":"Oncotarget"},{"issue":"15","key":"918_CR42","doi-asserted-by":"publisher","first-page":"19863","DOI":"10.18632\/oncotarget.7887","volume":"7","author":"P Wu","year":"2016","unstructured":"Wu P, Wu D, Zhao L, et al. Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis[J]. Oncotarget. 2016;7(15):19863\u201383.","journal-title":"Oncotarget"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00918-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-021-00918-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00918-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T19:09:41Z","timestamp":1675883381000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00918-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00918-6","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"3 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}